SCHEMBL86139

SCHEMBL86139

CCc1ccc(CCOC(C)=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
TSHR P16473 2/20 0.47
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 1/20 0.45
TYR P14679 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 1/20 0.42
PLK1 P53350 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2387794 0.84 NPC1 (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL8652676 0.84 LMNA (0.45) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL4242570 0.84 ALDH1A1 (0.62) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL7365104 0.84 ESR1 (0.56) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL86418 0.82 KMT2A (0.55) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4668894 0.82 ALDH1A1 (0.45) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL1067152 0.82 SIRT2 (0.47) ALDH1A1TSHRSMN1; SMN2MAPTTAAR1
SCHEMBL5691929 0.82 ALDH1A1 (0.41) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL5691933 0.82 LOXL2 (0.47) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2
SCHEMBL13777822 0.82 ALDH1A1 (0.41) ALDH1A1TSHRNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104353077-A Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative BOEHRINGER INGELHEIM INT 2015-02-18 CN disclosed
CN-104288166-A Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative BOEHRINGER INGELHEIM INT 2015-01-21 CN disclosed
US-20120141513-A1 DEUTERATED FINGOLIMOD CONCERT PHARMACEUTICALS INC. 2012-06-07 US disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
CN-101784270-A Pharmaceutical compositions comprising glucopyranosyl-substituted benzene derivatives BOEHRINGER INGELHEIM INT 2010-07-21 CN disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120141513-A1 DEUTERATED FINGOLIMOD S1PR1, S1PR3, S1PR4 ALDH1A1 2873/4885TSHR 652/4885NPC1 433/4885
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF HLA-B, HLA-A, HLA-C ALDH1A1 646/4885TSHR 1310/4885NPC1 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.